JP2022500461A5 - - Google Patents
Info
- Publication number
- JP2022500461A5 JP2022500461A5 JP2021514550A JP2021514550A JP2022500461A5 JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5 JP 2021514550 A JP2021514550 A JP 2021514550A JP 2021514550 A JP2021514550 A JP 2021514550A JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5
- Authority
- JP
- Japan
- Prior art keywords
- corneal region
- patient
- composition according
- dryness
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18196126.9 | 2018-09-22 | ||
| EP18196126 | 2018-09-22 | ||
| EP18198440 | 2018-10-03 | ||
| EP18198440.2 | 2018-10-03 | ||
| EP18202041.2 | 2018-10-23 | ||
| EP18202041 | 2018-10-23 | ||
| PCT/EP2019/075406 WO2020058504A1 (en) | 2018-09-22 | 2019-09-20 | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500461A JP2022500461A (ja) | 2022-01-04 |
| JP2022500461A5 true JP2022500461A5 (https=) | 2022-09-27 |
Family
ID=68240699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514550A Pending JP2022500461A (ja) | 2018-09-22 | 2019-09-20 | 眼表面の損傷および乾燥の症状の治療のための眼科用組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210346313A1 (https=) |
| EP (1) | EP3852734A1 (https=) |
| JP (1) | JP2022500461A (https=) |
| KR (1) | KR20210080388A (https=) |
| CN (1) | CN112739335A (https=) |
| AU (2) | AU2019342426A1 (https=) |
| CA (1) | CA3111873A1 (https=) |
| IL (1) | IL281516A (https=) |
| PH (1) | PH12021550621A1 (https=) |
| SG (1) | SG11202102818YA (https=) |
| WO (1) | WO2020058504A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| CA3036297C (en) | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2018055101A1 (en) | 2016-09-23 | 2018-03-29 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP4374851B1 (en) | 2016-12-23 | 2026-04-15 | Novaliq GmbH | Ophthalmic composition for treatment of dry eye disease |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| KR20200128407A (ko) | 2018-03-02 | 2020-11-12 | 노바리크 게엠베하 | 네비볼롤을 포함하는 약제학적 조성물 |
| SG11202007860XA (en) | 2018-03-28 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| EP1494681A4 (en) * | 2002-04-16 | 2008-08-06 | Collagenex Pharm Inc | PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA |
| EP2187900B1 (en) * | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| AU2013314303B2 (en) * | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CN113679699B (zh) * | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| JP5982070B1 (ja) * | 2014-10-09 | 2016-08-31 | 株式会社メディプロデュース | まつ毛用洗浄剤 |
| CN110403923B (zh) * | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| CA3036297C (en) * | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| WO2019068763A1 (en) * | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
-
2019
- 2019-09-20 WO PCT/EP2019/075406 patent/WO2020058504A1/en not_active Ceased
- 2019-09-20 CN CN201980062052.2A patent/CN112739335A/zh active Pending
- 2019-09-20 KR KR1020217011860A patent/KR20210080388A/ko active Pending
- 2019-09-20 JP JP2021514550A patent/JP2022500461A/ja active Pending
- 2019-09-20 CA CA3111873A patent/CA3111873A1/en active Pending
- 2019-09-20 AU AU2019342426A patent/AU2019342426A1/en not_active Abandoned
- 2019-09-20 SG SG11202102818YA patent/SG11202102818YA/en unknown
- 2019-09-20 EP EP19786907.6A patent/EP3852734A1/en active Pending
- 2019-09-20 US US17/278,585 patent/US20210346313A1/en active Pending
-
2021
- 2021-03-15 IL IL281516A patent/IL281516A/en unknown
- 2021-03-18 PH PH12021550621A patent/PH12021550621A1/en unknown
-
2025
- 2025-06-06 US US19/231,354 patent/US20250295607A1/en active Pending
- 2025-06-10 AU AU2025204313A patent/AU2025204313A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500461A5 (https=) | ||
| JP2022502421A5 (https=) | ||
| Murray et al. | The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis | |
| Baudouin et al. | Inflammation in Glaucoma: From the back to the front of the eye, and beyond | |
| Nijm et al. | Understanding the dual dilemma of dry eye and glaucoma: an international review | |
| JP2024116245A5 (https=) | ||
| Jaenen et al. | Ocular symptoms and signs with preserved and preservative-free glaucoma medications | |
| Park et al. | Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial | |
| Federici | The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| JP2015509500A5 (https=) | ||
| CA3072673A1 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| KR20210080388A (ko) | 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물 | |
| Lazreg et al. | Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications | |
| AU2020290443A1 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
| Voss et al. | Non-infectious and non-hereditary diseases of the corneal epithelium | |
| US20230338307A1 (en) | Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye | |
| Hashemian et al. | Ocular presentations of amyloidosis | |
| Bruce et al. | Anterior eye disease and therapeutics AZ | |
| El Fekih et al. | Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA) | |
| US20240216375A1 (en) | Use of sympathetic activation inhibitor and/or alpha 1-adrenergic receptor inhibitor in preparing medicine for treating dry eyes | |
| CN114040783A (zh) | 可用于治疗干眼症的组合物和方法 | |
| RU2021107208A (ru) | Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз | |
| Qian et al. | Efficacy of 0.05% cyclosporine A on tear inflammatory cytokines and goblet cell function after corneal refractive surgery | |
| JP5605072B2 (ja) | 角結膜疾患の予防又は治療剤 |